ES2336319T3 - Forma de dosificacion oral para la liberacion controlada de farmacos. - Google Patents

Forma de dosificacion oral para la liberacion controlada de farmacos. Download PDF

Info

Publication number: ES2336319T3
Authority: ES; Spain
Prior art keywords: dosage form; coating; core; oral dosage; form according
Prior art date: 2002-02-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES03739557T

Other languages

English (en)

Spanish (es)

Inventor

Luigi Martini

Vincenzo Re

Chi Leung Li

Helen Anne Willy

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Glaxo Group Ltd

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-12

Filing date

2003-02-12

Publication date

2010-04-12

2002-02-12 Priority claimed from GB0203298A external-priority patent/GB0203298D0/en

2002-02-12 Priority claimed from GB0203297A external-priority patent/GB0203297D0/en

2002-02-12 Priority claimed from GBGB0203296.9A external-priority patent/GB0203296D0/en

2003-02-12 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2010-04-12 Application granted granted Critical

2010-04-12 Publication of ES2336319T3 publication Critical patent/ES2336319T3/es

2023-02-12 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000006186 oral dosage form Substances 0.000 title claims abstract description 33
238000013270 controlled release Methods 0.000 title description 6
238000000576 coating method Methods 0.000 claims abstract description 90
239000011248 coating agent Substances 0.000 claims abstract description 88
150000003839 salts Chemical class 0.000 claims abstract description 55
239000012453 solvate Substances 0.000 claims abstract description 45
239000002552 dosage form Substances 0.000 claims abstract description 26
230000003628 erosive effect Effects 0.000 claims abstract description 14
239000000463 material Substances 0.000 claims description 16
238000000034 method Methods 0.000 claims description 16
230000001419 dependent effect Effects 0.000 claims description 14
HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical group N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 claims description 12
150000001875 compounds Chemical class 0.000 claims description 12
239000000203 mixture Substances 0.000 claims description 12
229940093257 valacyclovir Drugs 0.000 claims description 11
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 8
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
239000003795 chemical substances by application Substances 0.000 claims description 6
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
239000008101 lactose Substances 0.000 claims description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
229920000193 polymethacrylate Polymers 0.000 claims description 6
229920000642 polymer Polymers 0.000 claims description 5
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical group C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 4
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 4
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 4
229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 3
229940081734 cellulose acetate phthalate Drugs 0.000 claims description 3
239000004922 lacquer Substances 0.000 claims description 3
235000019359 magnesium stearate Nutrition 0.000 claims description 3
150000002688 maleic acid derivatives Chemical class 0.000 claims description 3
230000000149 penetrating effect Effects 0.000 claims description 3
229920002678 cellulose Polymers 0.000 claims description 2
229920001577 copolymer Polymers 0.000 claims description 2
239000004014 plasticizer Substances 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims description 2
229920002554 vinyl polymer Polymers 0.000 claims description 2
SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 claims 2
229910052710 silicon Inorganic materials 0.000 claims 2
239000010703 silicon Substances 0.000 claims 2
239000001913 cellulose Substances 0.000 claims 1
239000011162 core material Substances 0.000 description 61
239000002585 base Substances 0.000 description 36
239000003826 tablet Substances 0.000 description 26
229940126062 Compound A Drugs 0.000 description 21
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 21
239000003814 drug Substances 0.000 description 15
239000013543 active substance Substances 0.000 description 14
210000002784 stomach Anatomy 0.000 description 14
229940079593 drug Drugs 0.000 description 12
239000012530 fluid Substances 0.000 description 12
210000000936 intestine Anatomy 0.000 description 12
230000007613 environmental effect Effects 0.000 description 9
238000009472 formulation Methods 0.000 description 8
238000011282 treatment Methods 0.000 description 8
241000124008 Mammalia Species 0.000 description 7
-1 acyclovir L-valine ester Chemical class 0.000 description 7
238000003825 pressing Methods 0.000 description 7
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 6
SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 6
229920003134 Eudragit® polymer Polymers 0.000 description 5
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 5
238000004090 dissolution Methods 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
206010012601 diabetes mellitus Diseases 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
230000007935 neutral effect Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
230000001629 suppression Effects 0.000 description 4
230000009385 viral infection Effects 0.000 description 4
FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 3
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
208000009889 Herpes Simplex Diseases 0.000 description 3
208000007514 Herpes zoster Diseases 0.000 description 3
FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 3
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000002058 anti-hyperglycaemic effect Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
229960001058 bupropion Drugs 0.000 description 3
239000012458 free base Substances 0.000 description 3
239000012528 membrane Substances 0.000 description 3
229960005343 ondansetron Drugs 0.000 description 3
229960002296 paroxetine Drugs 0.000 description 3
238000011321 prophylaxis Methods 0.000 description 3
239000011347 resin Substances 0.000 description 3
229920005989 resin Polymers 0.000 description 3
210000000813 small intestine Anatomy 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
238000012546 transfer Methods 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
208000001688 Herpes Genitalis Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 2
229960004099 azithromycin Drugs 0.000 description 2
229920002301 cellulose acetate Polymers 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
201000004946 genital herpes Diseases 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000011148 porous material Substances 0.000 description 2
239000007921 spray Substances 0.000 description 2
125000005591 trimellitate group Chemical group 0.000 description 2
241001529453 unidentified herpesvirus Species 0.000 description 2
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
201000006082 Chickenpox Diseases 0.000 description 1
206010011831 Cytomegalovirus infection Diseases 0.000 description 1
102220570135 Histone PARylation factor 1_L30D_mutation Human genes 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-Valine Natural products CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229940123464 Thiazolidinedione Drugs 0.000 description 1
ZCDDBUOENGJMLV-QRPNPIFTSA-N Valacyclovir hydrochloride Chemical compound Cl.N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 ZCDDBUOENGJMLV-QRPNPIFTSA-N 0.000 description 1
206010046980 Varicella Diseases 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
WZNRVWBKYDHTKI-UHFFFAOYSA-N cellulose, acetate 1,2,4-benzenetricarboxylate Chemical compound OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.OC(=O)C1=CC(C(=O)O)=CC=C1C(=O)OCC1C(OC2C(C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(COC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)O2)OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)O1 WZNRVWBKYDHTKI-UHFFFAOYSA-N 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000003618 dip coating Methods 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000007922 dissolution test Methods 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
238000009503 electrostatic coating Methods 0.000 description 1
LUJQXGBDWAGQHS-UHFFFAOYSA-N ethenyl acetate;phthalic acid Chemical compound CC(=O)OC=C.OC(=O)C1=CC=CC=C1C(O)=O LUJQXGBDWAGQHS-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
230000000055 hyoplipidemic effect Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000003607 modifier Substances 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
229940096978 oral tablet Drugs 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000012545 processing Methods 0.000 description 1
125000004545 purin-9-yl group Chemical group N1=CN=C2N(C=NC2=C1)* 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
238000009495 sugar coating Methods 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
150000001467 thiazolidinediones Chemical class 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
229940064636 valacyclovir hydrochloride Drugs 0.000 description 1
229960004295 valine Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Obesity (AREA)
Virology (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

ES03739557T 2002-02-12 2003-02-12 Forma de dosificacion oral para la liberacion controlada de farmacos. Expired - Lifetime ES2336319T3 (es)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
GB0203298A GB0203298D0 (en)	2002-02-12	2002-02-12	Novel composition
GB0203297		2002-02-12
GB0203298		2002-02-12
GB0203297A GB0203297D0 (en)	2002-02-12	2002-02-12	Novel composition
GBGB0203296.9A GB0203296D0 (en)	2002-02-12	2002-02-12	Novel composition
GB0203296		2002-02-12

Publications (1)

Publication Number	Publication Date
ES2336319T3 true ES2336319T3 (es)	2010-04-12

Family

ID=27738830

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES03739557T Expired - Lifetime ES2336319T3 (es)	2002-02-12	2003-02-12	Forma de dosificacion oral para la liberacion controlada de farmacos.

Country Status (33)

Country	Link
EP (1)	EP1474114B1 (pt)
JP (2)	JP2005526031A (pt)
KR (2)	KR101048925B1 (pt)
CN (1)	CN100444833C (pt)
AP (1)	AP1736A (pt)
AR (1)	AR038417A1 (pt)
AT (1)	ATE455540T1 (pt)
AU (1)	AU2003245763B2 (pt)
BR (1)	BRPI0307319B8 (pt)
CA (1)	CA2475544A1 (pt)
CL (1)	CL2007003010A1 (pt)
CO (1)	CO5601025A2 (pt)
CY (1)	CY1109939T1 (pt)
DE (1)	DE60331041D1 (pt)
DK (1)	DK1474114T3 (pt)
EA (1)	EA008286B1 (pt)
EC (1)	ECSP045232A (pt)
ES (1)	ES2336319T3 (pt)
IL (1)	IL163098A (pt)
IS (1)	IS2747B (pt)
MA (1)	MA27689A1 (pt)
MX (1)	MXPA04007794A (pt)
MY (1)	MY139719A (pt)
NO (1)	NO334453B1 (pt)
NZ (1)	NZ534152A (pt)
OA (1)	OA12770A (pt)
PE (1)	PE20030800A1 (pt)
PL (1)	PL206596B1 (pt)
PT (1)	PT1474114E (pt)
SI (1)	SI1474114T1 (pt)
TW (1)	TWI286079B (pt)
UY (1)	UY27660A1 (pt)
WO (1)	WO2003068195A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0120835D0 (en)	2001-08-28	2001-10-17	Smithkline Beecham Plc	Process
GB0203296D0 (en)	2002-02-12	2002-03-27	Glaxo Group Ltd	Novel composition
US8637512B2 (en)	2002-07-29	2014-01-28	Glaxo Group Limited	Formulations and method of treatment
AR045330A1 (es) *	2003-08-07	2005-10-26	Sb Pharmco Inc	Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla
GB0318824D0 (en) *	2003-08-11	2003-09-10	Glaxo Group Ltd	Novel composition
US7879354B2 (en)	2004-01-13	2011-02-01	Mcneil-Ppc, Inc.	Rapidly disintegrating gelatinous coated tablets
JP5433236B2 (ja) *	2006-01-27	2014-03-05	アプタリスファーマテック，インコーポレイテッド	弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系
US20070196491A1 (en) *	2006-01-27	2007-08-23	Eurand, Inc.	Drug delivery systems comprising weakly basic drugs and organic acids

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2150830B (en) *	1983-12-05	1987-08-19	Alza Corp	Drug dispenser
GB8820353D0 (en) *	1988-08-26	1988-09-28	Staniforth J N	Controlled release tablet
US6099859A (en) *	1998-03-20	2000-08-08	Andrx Pharmaceuticals, Inc.	Controlled release oral tablet having a unitary core
DZ2937A1 (fr) *	1998-11-12	2004-03-15	Smithkline Beecham Plc	Compositions nouvelles de sensibilidants à l'insuline.
WO2000028989A1 (en) *	1998-11-12	2000-05-25	Smithkline Beecham P.L.C.	Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
GB0027471D0 (en) *	2000-11-08	2000-12-27	Smithkline Beecham Plc	Processes

2003
- 2003-02-10 MY MYPI20030447A patent/MY139719A/en unknown
- 2003-02-10 PE PE2003000145A patent/PE20030800A1/es active IP Right Grant
- 2003-02-11 UY UY27660A patent/UY27660A1/es not_active IP Right Cessation
- 2003-02-11 AR ARP030100422A patent/AR038417A1/es not_active Application Discontinuation
- 2003-02-11 TW TW092102772A patent/TWI286079B/zh not_active IP Right Cessation
- 2003-02-12 EP EP03739557A patent/EP1474114B1/en not_active Expired - Lifetime
- 2003-02-12 CN CNB038037378A patent/CN100444833C/zh not_active Expired - Lifetime
- 2003-02-12 AP APAP/P/2004/003087A patent/AP1736A/en active
- 2003-02-12 ES ES03739557T patent/ES2336319T3/es not_active Expired - Lifetime
- 2003-02-12 WO PCT/GB2003/000594 patent/WO2003068195A1/en not_active Ceased
- 2003-02-12 NZ NZ534152A patent/NZ534152A/en not_active IP Right Cessation
- 2003-02-12 AT AT03739557T patent/ATE455540T1/de active
- 2003-02-12 CA CA002475544A patent/CA2475544A1/en not_active Abandoned
- 2003-02-12 BR BRPI0307319A patent/BRPI0307319B8/pt not_active IP Right Cessation
- 2003-02-12 PT PT03739557T patent/PT1474114E/pt unknown
- 2003-02-12 PL PL371368A patent/PL206596B1/pl unknown
- 2003-02-12 MX MXPA04007794A patent/MXPA04007794A/es active IP Right Grant
- 2003-02-12 OA OA1200400209A patent/OA12770A/en unknown
- 2003-02-12 KR KR1020047012361A patent/KR101048925B1/ko not_active Expired - Lifetime
- 2003-02-12 EA EA200401071A patent/EA008286B1/ru not_active IP Right Cessation
- 2003-02-12 KR KR1020107015064A patent/KR20100086084A/ko not_active Ceased
- 2003-02-12 AU AU2003245763A patent/AU2003245763B2/en not_active Expired
- 2003-02-12 SI SI200331764T patent/SI1474114T1/sl unknown
- 2003-02-12 JP JP2003567378A patent/JP2005526031A/ja not_active Withdrawn
- 2003-02-12 DE DE60331041T patent/DE60331041D1/de not_active Expired - Lifetime
- 2003-02-12 DK DK03739557.1T patent/DK1474114T3/da active
2004
- 2004-07-19 IL IL163098A patent/IL163098A/en active IP Right Grant
- 2004-08-05 IS IS7383A patent/IS2747B/is unknown
- 2004-08-09 CO CO04077244A patent/CO5601025A2/es not_active Application Discontinuation
- 2004-08-12 MA MA27822A patent/MA27689A1/fr unknown
- 2004-08-12 EC EC2004005232A patent/ECSP045232A/es unknown
- 2004-08-31 NO NO20043633A patent/NO334453B1/no not_active IP Right Cessation
2007
- 2007-10-19 CL CL2007003010A patent/CL2007003010A1/es unknown
2010
- 2010-03-31 CY CY20101100304T patent/CY1109939T1/el unknown
- 2010-04-22 JP JP2010098906A patent/JP5279757B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP1474114B1 (en)	2010-01-20
OA12770A (en)	2006-07-04
CY1109939T1 (el)	2014-09-10
JP5279757B2 (ja)	2013-09-04
BRPI0307319B8 (pt)	2021-05-25
NZ534152A (en)	2006-11-30
DE60331041D1 (de)	2010-03-11
EA200401071A1 (ru)	2004-12-30
PL206596B1 (pl)	2010-08-31
JP2010159301A (ja)	2010-07-22
AU2003245763B2 (en)	2008-12-11
KR20040084900A (ko)	2004-10-06
PL371368A1 (en)	2005-06-13
PE20030800A1 (es)	2003-10-31
SI1474114T1 (sl)	2010-04-30
NO20043633L (no)	2004-10-27
IS2747B (is)	2011-08-15
ECSP045232A (es)	2004-09-28
MY139719A (en)	2009-10-30
CL2007003010A1 (es)	2008-01-25
CA2475544A1 (en)	2003-08-21
AU2003245763A1 (en)	2003-09-04
UY27660A1 (es)	2003-09-30
CO5601025A2 (es)	2006-01-31
MXPA04007794A (es)	2004-10-15
NO334453B1 (no)	2014-03-03
TWI286079B (en)	2007-09-01
AP2004003087A0 (en)	2004-09-30
ATE455540T1 (de)	2010-02-15
DK1474114T3 (da)	2010-04-12
PT1474114E (pt)	2010-03-04
IS7383A (is)	2004-08-05
BR0307319A (pt)	2005-01-04
JP2005526031A (ja)	2005-09-02
BRPI0307319B1 (pt)	2018-05-02
MA27689A1 (fr)	2006-01-02
AR038417A1 (es)	2005-01-12
EA008286B1 (ru)	2007-04-27
CN100444833C (zh)	2008-12-24
CN1655768A (zh)	2005-08-17
WO2003068195A1 (en)	2003-08-21
EP1474114A1 (en)	2004-11-10
AP1736A (en)	2007-05-02
TW200307567A (en)	2003-12-16
HK1072194A1 (en)	2005-08-19
KR101048925B1 (ko)	2011-07-12
IL163098A (en)	2009-05-04
KR20100086084A (ko)	2010-07-29

Publication	Publication Date	Title
US9144547B2 (en)	2015-09-29	Oral dosage form for controlled drug release
ES2541124T3 (es)	2015-07-16	Nueva formulación farmacéutica que contiene una biguanida y un derivado de tiazolidinodiona
JP5279757B2 (ja)	2013-09-04	薬物制御放出のための経口用剤形
ES2339554T3 (es)	2010-05-21	Composicion que comprende rosiglitazona y metformina.
AU2004262926B2 (en)	2009-11-19	Composition for releasing a weak base for an extended period of time
CA2595411A1 (en)	2006-08-24	Oral dosage form comprising rosiglitazone
HK1072194B (en)	2010-06-04	Oral dosage form for controlled drug release
ES2382551T3 (es)	2012-06-11	Sistema de administración de fármacos orales